<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489342</url>
  </required_header>
  <id_info>
    <org_study_id>WesternHSCT</org_study_id>
    <nct_id>NCT04489342</nct_id>
  </id_info>
  <brief_title>Advanced Sensor Based Functional ASsessmenTs in Axial Spondyloarthritis</brief_title>
  <acronym>ASFASTAS</acronym>
  <official_title>An Investigation Into the Responsiveness of Inertial Measurement Unit (IMU) Sensor-based Tests in Measuring Changes in Spinal Mobility and Function in Axial Spondyloarthritis Patients Treated With Biologic Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Health and Social Care Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ulster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Western Health and Social Care Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study using Inertial Measurement Unit (IMU) sensors to measure the&#xD;
      effects of biological therapy on spinal mobility and function in axial spondyloarthritis.&#xD;
      Participants will undergo MRI scans before and after therapy in parallel to the sensor tests&#xD;
      to establish correlation between changes in inflammatory signs and changes in spinal&#xD;
      mobility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will study 20 participants with active axial spondyloarthritis (axSpA) who are about to&#xD;
      start biologic therapy as part of routine care. In brief, we will carry out the following&#xD;
      assessments before and after therapy:&#xD;
&#xD;
        1. MRI of spine and Sacroiliac (SI) joints - modified Stoke Ankylosing Spondylitis Spine&#xD;
           Score (mSASSS) scoring&#xD;
&#xD;
        2. Record standard Patient recorded outcomes (PROs): Bath Ankylosing Spondylitis Disease&#xD;
           Activity Index (BASDAI), Bath Ankylosing Global (BASG), Bath Ankylosing Spondylitis&#xD;
           Metrology Index (BASMI), Bath Ankylosing Spondylitis Functional Index (BASFI),&#xD;
           Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Disease&#xD;
           Activity Score Health Index (ASAS-HI), Euroquol 3 level health assessment (EQ5D-3L),&#xD;
           work productivity and activity impairment questionnaire (WPAI), Short QUestionnaire to&#xD;
           ASsess Health enhancing physical activity (SQUASH),&#xD;
&#xD;
        3. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)&#xD;
&#xD;
        4. IMU sensor tests in clinic for range of motion (ROM) in cervical, thoracic and lumbar&#xD;
           spine.&#xD;
&#xD;
        5. IMU sensor tests at home for standardised function testing&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">February 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 7, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in composite IMU sensor based metrology index (IMU-ASMI)</measure>
    <time_frame>4 months</time_frame>
    <description>Change in AxSpA metrology index based on sensor tests of Range of Movement (i.e. spinal mobility). Scale 0-10, with 10 being severe loss of spinal mobility.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Metrology Index (BASMI)</measure>
    <time_frame>4 months</time_frame>
    <description>Change in traditional metrology index of spinal mobility. Scale 0-10, with 10 being severe loss of spinal mobility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</measure>
    <time_frame>4 months</time_frame>
    <description>Change in axSpA disease activity. BASDAI scale 0-10, 10 representing high disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Assessment of Spondyloarthritis International Society Response Criteria (ASAS20)</measure>
    <time_frame>4 months</time_frame>
    <description>Change in axSpA disease activity response - 20% improvement is regarded as minimum improvement in at least three of Patient global assessment, Pain assessment, BASFI and Inflammation (last two questions of BASDAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)</measure>
    <time_frame>4 months</time_frame>
    <description>Change in MRI score of inflammation. Range 0-72 the sum of scores for 24 vertebral edges in the lumbar and cervical regions, higher represents more spinal damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Functional Index (BASFI)</measure>
    <time_frame>4 months</time_frame>
    <description>Change in traditional questionnaire function assessment 0-10 scale, 10 representing a high degree of functional impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sit to Stand Test Scores</measure>
    <time_frame>4 months</time_frame>
    <description>Change in standardised function score. Time taken to complete 5 sit to stand actions from a seated position on a chair at standard height.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IMU sensor test</intervention_name>
    <description>Measurement of maximum range of movement in the spine; Ambulatory observational data while performing standardised functional tests</description>
    <other_name>ViMove (DorsaVi)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with active axSpA (BASDAI &gt;4, Spinal Pain VAS &gt;4)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of axial spondyloarthritis fulfilling ASAS classification criteria.&#xD;
&#xD;
          2. Age â‰¥18 years old and &lt;80 years.&#xD;
&#xD;
          3. Fulfilment of local criteria for biologic therapy for axSpA.&#xD;
&#xD;
          4. The subjects should be able to read, write, understand and complete study&#xD;
             questionnaires.&#xD;
&#xD;
          5. Each subject must sign an informed consent form (ICF) indicating that he or she&#xD;
             understands the purpose of and procedures required for the study and are willing to&#xD;
             participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Safety contra-indication for biologic drug therapy.&#xD;
&#xD;
          2. Severely restricted hip movement (less than 20 degrees rotation in either hip).&#xD;
&#xD;
          3. History of previous clinical (symptomatic) vertebral fracture.&#xD;
&#xD;
          4. History of previous spinal surgery.&#xD;
&#xD;
          5. History of previous hip replacement surgery.&#xD;
&#xD;
          6. Major scoliosis deformity (in the opinion of the investigator).&#xD;
&#xD;
          7. Safety contra-indication for MRI assessment.&#xD;
&#xD;
          8. Previous biologic agent within 2 months.&#xD;
&#xD;
          9. Pregnant or breast-feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Philip Gardiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Health and Social Care Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dawn Small</last_name>
    <phone>02871345171</phone>
    <email>Dawn.Small@westerntrust.hscni.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aaron Peace, MD</last_name>
    <phone>02871345171</phone>
    <email>aaron.peace@westerntrust.hscni.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Rheumatology, Altnagelvin Hospital</name>
      <address>
        <city>Londonderry</city>
        <state>N.Ireland</state>
        <zip>BT47 6SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip V Gardiner, MD FRCP</last_name>
      <phone>02871345171</phone>
      <phone_ext>213618</phone_ext>
      <email>philip.gardiner@westerntrust.hscni.net</email>
    </contact>
    <investigator>
      <last_name>Philip V Gardiner, MB MD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Health and Social Care Trust</investigator_affiliation>
    <investigator_full_name>Dr Philip Gardiner</investigator_full_name>
    <investigator_title>Consultant Rheumatologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Willing to share details of results and analyses with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

